Skip to main content

Table 1 Patient characteristics

From: Nocturnal CPAP improves walking capacity in COPD patients with obstructive sleep apnoea

  Overlap syndrome n = 22 COPD n = 22 p-value
Age 70.0 ± 8.3 71.7 ± 8.5 0.495
Male, n (%) 21 (96.7) 22 (100) 0.999
BMI 24.9 ± 3.5 22.9 ± 3.0 0.054
Smoking, pack-years 52.3 ± 21.5 50.8 ± 26.4 0.837
ESS 12.7 ± 4.5 8.3 ± 3.5 0.004
PSQ 11.8 ± 4.0 7.5 ± 3.7 0.001
Emphysema predominant, n (%) 5 (22.7) 14 (63.6) 0.014
Pulmonary function test    
FEV1/FVC 57.5 ± 12.7 54.5 ± 9.6 0.197
FEV1 (L) 1.09 ± 0.51 0.95 ± 0.45 0.227
FEV1 (% predicted) 52.7 ± 28.6 45.1 ± 19.2 0.431
FVC (L) 1.87 ± 0.69 1.70 ± 0.60 0.348
FVC (% predicted) 63.3 ± 25.1 57.2 ± 21.7 0.378
Arterial blood gas    
pH 7.4 ± 0.0 7.4 ± 0.0 0.672
PaCO2 (mm Hg) 41.8 ± 3.8 40.6 ± 3.8 0.354
PaO2 (mmHg) 77.5 ± 11.9 79.2 ± 9.0 0.581
Medication    
LABA + ICS, n (%) 20 (90.9) 19 (86.4) 0.565
LAMA, n (%) 18 (81.8) 17 (77.3) 0.907
Theophyllines, n (%) 6 (27.3) 2 (9.1) 0.375
Comorbidities    
DM, n (%) 0 (0) 1 (4.5) -
HTN, n (%) 10 (45.4) 8 (36.4) 0.348
CAD, n (%) 1 (4.5) 1 (4.5) 0.823
PAOD, n (%) 0 (0) 0 (0) -
  1. Data are presented as mean ± SD, or number (percentage).
  2. BMI body mass index, ESS Epworth sleepiness scale, PSQ Pittsburg sleep quality, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ICS inhaled corticosteroids, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, DM diabetes mellitus, HTN hypertension, CAD coronary artery disease, PAOD peripheral arterial occlusion disease.